focus -WSS

focus

author：knowledge 2025-10-06 14:17:09 Page View：21258

close-up of psoriasis on a hand. -- biotech coverage from STAT — A close-up of psoriasis on a hand. Adobe

San Francisco startup Alumis Inc. has raised $259 million in a bid to best big pharma’s work in plaque psoriasis.

Alumis announced its Series C round Wednesday and plans to move its lead drug into Phase 3 trials. Venture firm Foresite Capital, which incubated Alumis, co-led the financing with Samsara BioCapital and venBio Partners.

Alumis’ lead drug, ESK-001, is an oral medicine designed to help patients with the most common type of psoriasis by inhibiting a signaling protein called TYK2. Research has shown that the TYK2 protein plays a role in diseases where the immune system overreacts, which has made it a popular drug target in recent years.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： ‘We were in the air.’ Mississippi family recounts surviving tornado that tore mobile home apart
Next article： Duchenne breakthrough therapy leaves behind pioneering families

focus

Wildfire smoke exposes gaps in outdoor worker protections

ApersonwaitingforthesubwaywearsafilteredmaskassmokyhazefromwildfiresinCanadablanketsaneighborhoodinN

Marc Tessier

AdamFagenLastweek,MarcTessier-LavigneannouncedthathewillresignaspresidentofStanfordoverworkperformed

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

6:16PresidentJoeBidenspeaksintheRooseveltRoomoftheWhiteHouse,June30,2023.EvanVucci/APPresidentJoeBid

'Disease catastrophe' looms in Sudan as health conditions deteriorate, medics warn

1:30Aboywalksthroughafloodedareainal-SagainorthofOmdurmanonAugust6,2023.Torrentialrainshavedestroyed

focus

explore

focus

'Disease catastrophe' looms in Sudan as health conditions deteriorate, medics warn